Q-omics provides the consensus-scored NRDC profile across patient tissues and cancer cell-line models. NRDC expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NRDC is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, NRDC protein abundance shows 28,752 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where NRDC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRDC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRDC survival associations across molecular data types. NRDC RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRDC RNA expression–survival associations across cancer types. High NRDC expression shows unfavorable associations in MESO, KICH, KIRP, ACC, BLCA and UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NRDC RNA expression.
This table summarizes NRDC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NRDC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRDC shows higher tumor expression in KIRC, HNSC, LIHC, LUAD, LUSC and STAD. The KIRC box plot shows higher NRDC RNA expression in tumor versus normal tissue (log2 FC = +0.509, t-test p < 0.001).
This table shows molecular features associated with NRDC in patient tissues and cancer cell lines. In patient samples, NRDC shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NRDC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
